TY - JOUR
T1 - Legal obstacles jeopardise research in personalised medicine – experiences from a Nordic collaboration within rheumatology
AU - Glintborg, Bente
AU - Hansson, Mats
AU - Hammer, Hilde Berner
AU - Klareskog, Lars
AU - Saevarsdottir, Saedis
AU - Westerlind, Helga
AU - Rönnelid, Johan
AU - Gehring, Isabel
AU - Benson, Mikael
AU - Esbensen, Bente Appel
AU - Hetland, Merete Lund
AU - Padyukov, Leonid
AU - Kragstrup, Tue Wenzel
AU - Hauge, Ellen Margrethe
AU - AxnÄs, Barbara Bislawska
AU - Krogh, Niels Steen
AU - Johannesson, Martina
AU - Askling, Johan
N1 - Publisher Copyright:
© Author(s) 2023.
PY - 2024/12
Y1 - 2024/12
N2 - Aims: Personalised medicine in chronic complex diseases such as rheumatoid arthritis (RA) is within reach but requires international multi-stakeholder collaboration. We exemplify how national implementations of the General Data Protection Regulation (GDPR) have introduced administrative delays and created disincentives for data sharing and collaborative research. Methods: Our Danish/Swedish/Norwegian research collaboration (the 3-year NordForsk-funded “NORA” project) aims to develop a personalised medicine approach for the management of RA, built on the exploitation of unique existing data sources: longitudinal data from clinical rheumatology registries, research cohorts, nationwide health care registries, and biobank material from >20 sample collections. Data and results are shared and accessed remotely by collaborators at secure servers. New biomarker assays and patient-centric implementations of the results are to be explored, validated, and disseminated to patients and health care via the development of digital tools. Results: Following the advice of legal experts at the involved academic or public institutions and private companies, GDPR compliance resulted in >20 legal documents to govern the collaboration (consortium-, joint controller-, research collaboration-, data sharing-, and a series of unique two-way data processing-, and material transfer agreements). Lack of agreed-upon templates, policies, procedures, and a shortage of legal resources have caused considerable delays. Thus, our research consortium has spent more time ensuring GDPR compliance than on actual research activities. Conclusions: The current interpretation and implementation of the legal premises (rather than the GDPR per se) for research collaborations caused unnecessary barriers and delays. Our experiences call for Nordic trust-based code-of-conduct-like framework agreements, and for harmonisation of procedures and templates, lest the Nordic advantage in research be lost.
AB - Aims: Personalised medicine in chronic complex diseases such as rheumatoid arthritis (RA) is within reach but requires international multi-stakeholder collaboration. We exemplify how national implementations of the General Data Protection Regulation (GDPR) have introduced administrative delays and created disincentives for data sharing and collaborative research. Methods: Our Danish/Swedish/Norwegian research collaboration (the 3-year NordForsk-funded “NORA” project) aims to develop a personalised medicine approach for the management of RA, built on the exploitation of unique existing data sources: longitudinal data from clinical rheumatology registries, research cohorts, nationwide health care registries, and biobank material from >20 sample collections. Data and results are shared and accessed remotely by collaborators at secure servers. New biomarker assays and patient-centric implementations of the results are to be explored, validated, and disseminated to patients and health care via the development of digital tools. Results: Following the advice of legal experts at the involved academic or public institutions and private companies, GDPR compliance resulted in >20 legal documents to govern the collaboration (consortium-, joint controller-, research collaboration-, data sharing-, and a series of unique two-way data processing-, and material transfer agreements). Lack of agreed-upon templates, policies, procedures, and a shortage of legal resources have caused considerable delays. Thus, our research consortium has spent more time ensuring GDPR compliance than on actual research activities. Conclusions: The current interpretation and implementation of the legal premises (rather than the GDPR per se) for research collaborations caused unnecessary barriers and delays. Our experiences call for Nordic trust-based code-of-conduct-like framework agreements, and for harmonisation of procedures and templates, lest the Nordic advantage in research be lost.
KW - biobank
KW - GDPR
KW - legal infrastructure
KW - Nordic collaboration
KW - Personalised medicine
KW - rheumatoid arthritis
UR - http://www.scopus.com/inward/record.url?scp=85211772677&partnerID=8YFLogxK
U2 - 10.1177/14034948231212711
DO - 10.1177/14034948231212711
M3 - Comment/debate
AN - SCOPUS:85211772677
SN - 1403-4948
VL - 52
SP - 1019
EP - 1025
JO - Scandinavian Journal of Public Health
JF - Scandinavian Journal of Public Health
IS - 8
ER -